Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Texas MPN Workshop 2021 | Promising trials in polycythemia vera

Abdulraheem Yacoub • 10 Aug 2021
Texas MPN Workshop 2021
Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Givinostat Hydroxyurea Interferon Ropeginterferon alfa-2b

Abdulraheem Yacoub, MD, MBBS, The University of Kansas, Westwood, KS, discusses upcoming trials investigating the treatment of polycythemia vera, namely trials exploring pegylated interferons and hepcidin inhibitors which have reported promising preliminary clinical outcomes. In particular, Dr Yacoub comments on the potential benefits of ropeginterferon alfa-2b, which is currently approved in Europe but not in the US. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.

More from Abdulraheem Yacoub

2:06
Parsaclisib plus ruxolitinib in myelofibrosis: a promising strategy for treatment-naive patients
Abdulraheem Yacoub • 26 Aug 2022
2:42
The management of advanced phase MPNs
Abdulraheem Yacoub • 26 Aug 2022
4:15
The latest data on momelotinib for MPNs
Abdulraheem Yacoub • 10 Aug 2021
4:11
Novel therapies and combinations for myelofibrosis patients
Abdulraheem Yacoub • 10 Aug 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals